

The Unrecognised Revolution in Global Health

An update on the state of the neglected disease R&D product pipeline

Dr Nick Chapman

Director of Research, Policy Cures

Berlin, 13 October 2015




Current state of the neglected disease R&D pipeline

The R&D pipeline for neglected diseases is healthier now than it has ever been


485

product candidates
in the pipeline



Current state of the neglected disease R&D pipeline

It is largely being driven by public health goals



80% of all candidates have a public sector partner

Current state of the neglected disease R&D pipeline

PDPs are involved in the development of:

40% of all pipeline candidates

68% of all public-private partnered candidates

This is despite the fact that PDPs received only 15% of total funding for neglected disease R&D in 2013

Current state of the neglected disease R&D pipeline

Industry is playing a critical role


59% of all candidates in the pipeline have an industry partner

... mostly in partnership with the public sector

Two thirds of all industry involvement is in partnership with the public sector

Current state of the neglected disease R&D pipeline

It is highly concentrated on just three diseases (malaria, TB, and HIV/AIDS)



What does this mean?

The current model is working

... and this needs both recognition and support

What does this mean?

That is not to say that there is not room for improvement

- Better funding
- Better prioritisation

What does this mean?

With sustained, appropriate support, we will see the delivery of many exciting transformative technologies over the next 15 years